New Biologics for Severe Asthma: What Patients, What Agents, What Results, at What Cost?
- PMID: 30407843
- DOI: 10.1164/rccm.201810-1974ED
New Biologics for Severe Asthma: What Patients, What Agents, What Results, at What Cost?
Comment on
-
Predicting Responders to Reslizumab after 16 Weeks of Treatment Using an Algorithm Derived from Clinical Studies of Patients with Severe Eosinophilic Asthma.Am J Respir Crit Care Med. 2019 Feb 15;199(4):489-495. doi: 10.1164/rccm.201708-1668OC. Am J Respir Crit Care Med. 2019. PMID: 30346831
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
